Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

NCT03914300 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

11

Enrollment

NIH

Sponsor class

Conditions

Differentiated Thyroid Gland Carcinoma
Follicular Variant Thyroid Gland Papillary Carcinoma
Poorly Differentiated Thyroid Gland Carcinoma
Refractory Differentiated Thyroid Gland Carcinoma
Refractory Thyroid Gland Carcinoma
Tall Cell Variant Thyroid Gland Papillary Carcinoma
Thyroid Gland Follicular Carcinoma
Thyroid Gland Oncocytic Carcinoma
Thyroid Gland Papillary Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Cabozantinib S-malate
PROCEDURE: Computed Tomography
BIOLOGICAL: Ipilimumab
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)